1 / 15

Comparison of Angio JET Rheolytic Thrombectomy

Comparison of Angio JET Rheolytic Thrombectomy Before Direct Infarct Artery STENT ing in Patients with Acute Myocardial Infarction : the JETSTENT trial. David Antoniucci on behalf of the JETSTENT Investigators. JETSTENT TRIAL.

nasim-riddle
Télécharger la présentation

Comparison of Angio JET Rheolytic Thrombectomy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ComparisonofAngioJETRheolyticThrombectomy BeforeDirectInfarctArterySTENTing in Patientswith Acute MyocardialInfarction: the JETSTENT trial David Antoniucci on behalf of the JETSTENT Investigators

  2. JETSTENT TRIAL • Steering Committe: D Antoniucci (PI), A Colombo (PI), F-J Neumann, A Rodriguez, A Stabile, J Gustafson • Data monitoring and management and Core Labs: MCR (EKG, Angio), Florence University (Nuclear) • Clinical event adjudication committee: GB Danzi (I), C Di Mario (UK), and I Moussa (USA) • Country sites:  Italy (4); Argentina (1); Germany (1); Poland (3). • Sponsor: Medrad Interventional/Possis

  3. Study Design Pts with STEMI admitted within 12 hours from symptom onset • Lysis • Stroke < 30 days • Surgery < 6 weeks • Pre-stented IRA After angiography and IRA wiring: thrombus grade 3 to 5 Randomization 1:1 Direct Stenting (DS) Rheolytic Thrombectomy +DS N = 500

  4. JETSTENT TRIAL • Primary surrogate end points: • Early ST-segment resolution (≥ 50% ST segment elevation reduction at 30 minutes) • Infarct size (1-month 99mTc sestamibi scintigraphy) • Clinical end points: • MACCE at 1, 6, and 12 months, • Death and Readmission for HCF at 12 months • Secondary surrogate end points: • TIMI flow, cTFC, and TIMI blush

  5. Baseline Characteristics • RT DS • n=256n=245p value • Age (yrs) 63.0 ± 12.3 64.3 ± 11.5 .208 • Sex (male) 195 (76) 199 (81) .168 • Hypertension 120 (47) 116 (47) .916 • Dyslipidemia 77 (30) 85 (35) .270 • Diabetes mellitus 36 (14) 37 (15) .742 • Previous MI 10 (3.9) 12 (4.9) .588 • Anterior MI 101 (39) 91 (37) .595 • Cardiogenic shock 7 (2.7) 13 (5.3) .142 • ST elevation (mm) 3.98 ± 2.49 4.02 ± 2.69 .886 • Symptom-ER (min)125 [85-221.5] 135 [85.7-226.7] .853

  6. Baseline Angiographic Characteristics • RT DS • n=256n=245p value • Multivessel disease 114 (44) 95 (39) .192 • IRA .483 • LAD 107 (42) 91 (37) • RCA 112 (44) 120 (49) • LCx 37 (14) 34 (14) • RVD (mm) 2.94 [2.67-3.24] 2.91 [2.62-3.25] .670 • Pre-wiring TIMI flow 0-1 212/254(83.5) 203/242(83.9) .899 • Post-wiring TIMI flow 0-1 142/231 (61.4) 129/222 (58.1) .465 • Thrombusgrade.640 • 1-2 3 (1.4) 3 (1.4) • 3 73 (32.5) 80 (37.4) • 4 83 (37.4) 79 (36.9) • 5 63 (28.4) 52 (24.3)

  7. ProceduralCharacteristics • RT DS • n=256n=245 p value • ER-PCI (min) 34 [15-67] 31 [18-60] .727 • Proceduraltime (min) 59.5 [44.7-70] 46 [35-60] <.001 • Predilationbefore RT 5/246 (2) • TIMI flow 3 after RT 159/ 222 (72) • Predilationbeforestenting 25 (9.8) 34 (13.9) .149 • Stent per pt 1.26 ± 0.54 1.40 ± 0.73 .022 • Meanstentlength (mm) 23.7 ± 10.9 25.9 ± 14.1 .050 • Abciximab 249 (97) 239 (98) .841 • Procedural success 237 (93) 229 (93) .696

  8. Complications • RT DS • n=256n=245p value • Major bleeding (TIMI criteria) 10 (3.9) 4 (1.6) .123 • RT related pacing 2 (0.08) - .165 • Perforation 0 1* (0.04) .327 • *Covered stent.

  9. Surrogate Endpoints • RT DS • n=246 n=240 • ST ≥ 50% at 30 min 85.8% 78.8% .043 • n=217 n=208 • InfarctSize (%) 11.8 [3.1-23.7]12.7 [4.7-23.3] .398 • n=252 n=241 • Final TIMI 3 flow 203 (80.6) 207 (85.9) .113 • n=228 n=216 • cTFC 20 [15.0-27.2] 20 [14.0-25.7] .357 n=215 n=211 • Blush grade .207 • 0-1 17 (8) 11 (5) • 243 (20) 33 (16) • 3155 (72) 167 (79)

  10. Early ST Resolution and MACCE • Non-STRSTR p value • 1-monthn=86 n=400 • Death 6 (7.0) 5 (1.3) .001 • MACCE 10 (11.6) 15 (3.8) .003 • 6-monthsn=80 n=365 • Death 8 (10.0) 10 (2.7) .003 • MACCE 22 (27.5) 53 (14.5) .005

  11. One-MonthOutcome P = 0.050

  12. 6-Month Outcome RT DS

  13. PredictorsofST-segmentResolutionand 1-month MACCE Logisticregression (forwardstepwise) • 30 min. ST Reduction≥ 50% (n=471)OR 95%CI p value • Randomizationto RT 1.81 1.09 – 3.00 .022 • Anterior AMI 0.28 0.17 – 0.46 <.001 • Abciximab 4.28 1.22 – 14.95 .023 • TIMI 3 flow 2.10 1.17 - 3.80 .013 • 1-month MACCE (n=486)OR 95%CI p value • Randomizationto RT 0.30 0.11 – 0.80 .017 • Abciximab 0.10 0.02 – 0.43 .002 • TIMI 3 flow 0.16 0.06 – 0.41 <.001 • Bleeding 9.11 2.17 – 38.17 .003

  14. Six-month MACCE Kaplan-Meier Estimate 100 80.7 ± 4.1 (%) 90 Log-rank test p=0.007 N=464 EventsRT = 28 EventsDS = 47 80 70 RT 64.1 ± 6.0 DS 60 Time (days) 50 0 30 60 90 120 150 180 210 240

  15. Conclusions • Rheolyticthrombectomy before direct IRA stenting as compared to direct IRA stenting alone is associated with a better myocardial reperfusion (higher early ST-segment resolution rate) and 6-month clinical outcome (lower MACCE rate). • The results of the JETSTENT trial support the routine use of rheolyticthrombectomy in STEMI patients with evidence of thrombus.

More Related